Institut für Zellbiologie und Immunologie, Universität Stuttgart, Germany.
BioDrugs. 2010 Apr 1;24(2):89-98. doi: 10.2165/11530960-000000000-00000.
The concept of using bispecific antibodies to retarget immune effector cells for cancer therapy was conceived more than 20 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe adverse effects and immunogenicity of the bispecific antibodies. A deeper understanding of effector cell biology and especially developments in the field of antibody engineering has led to the generation of new classes of bispecific antibodies capable of circumventing many of these obstacles. Furthermore, new applications were established for bispecific antibodies, such as pre-targeting strategies in radioimmunotherapy or dual targeting approaches in order to improve binding, selectivity, and efficacy. This review summarizes recent progress in the development of bispecific antibodies and describes some new concepts developed for cancer immunotherapy.
将双特异性抗体用于重定向免疫效应细胞以进行癌症治疗的概念早在 20 多年前就已经提出。然而，最初的临床研究结果相当令人失望，主要是由于双特异性抗体的疗效低、严重的副作用和免疫原性。对效应细胞生物学的更深入了解，特别是在抗体工程领域的发展，导致了能够规避许多这些障碍的新型双特异性抗体的产生。此外，双特异性抗体还开辟了新的应用领域，例如放射免疫治疗中的前靶向策略或双重靶向方法，以提高结合、选择性和疗效。本文综述了双特异性抗体开发的最新进展，并描述了一些为癌症免疫治疗开发的新概念。
